High resolution, in situ platform to combine single-cell and spatial genomics analyses

A Contract Award Notice
by UNIVERSITY OF MANCHESTER

Source: Find a Tender
Type: Contract (Goods)
Duration: not specified
Value: £428K

Sector: HEALTH
Published: 14 Jun 2023
Delivery: not specified
Deadline: n/a

Concepts

Location

Greater Manchester: The University of Manchester

Geochart for 1 buyers and 1 suppliers

1 buyer

Manchester University Manchester

1 supplier

Vizgen Cambridge

Description

The high resolution, in situ platform to combine single-cell and spatial genomics analyses, is required by the Genomic Technologies Core Facility (GTCF). Enabling multiplexed, error-robust, single-cell in situ transcriptomic imaging from whole tissue to subcellular resolution.

Total Quantity or Scope

Research - Genomic Technologies Core Facility (GTCF)

Award Detail

1	Vizgen (Cambridge) High resolution, in situ platform to combine single-cell and spatial genomics analyses Reference: 016817-2023-1 Value: £428,000

CPV Codes

33000000 - Medical equipments, pharmaceuticals and personal care products
33100000 - Medical equipments

Legal Justification

The High resolution in situ platform to combine single-cell and spatial genomics analyses, is required by the Genomic Technologies Core Facility The High resolution in situ platform to combine single-cell and spatial genomics analyses is provided by Vizgen Inc., who are the sole provider of the MERSCOPE Platform. MERSCOPE is the MERFISH technology platform solution developed by the supplier. The MERSCOPE Platform is powered by MERFISH (Multiplexed Error Robust in situ Hybridization) technology, which is exclusively licensed to Vizgen by Harvard University for commercialisation. This solution enables multiplexed, error-robust, single-cell in situ transcriptomic imaging from whole tissue to subcellular resolution. This product and it's use is covered by U.S. patents